TP3011

Cat. No.:	HY-135845
CAS No.:	534605-74-8
Molecular Formula:	$C_{26}H_{26}N_4O_5$
Molecular Weight:	474.51
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TP3011 (CH0793011) is an active metabolite of CH-0793076 and is a potent topoisomerase I inhibitor equipotent as SN38[1]. TP3011 is against cancer cell lines growth with IC_{50}s at the range sub-nanomolar in vitro[2].
IC_{50} & Target	Topoisomerase I
In Vitro	TP3011 (0-100 nM; 72 hours) (compound 6c) inhibits cell proliferative activities against various human cancer cell lines, producing 50% inhibition (IC_{50}) of cell growth of 0.85 nM; 8.5 nM; and 8.2 nM in HCT116, QG56, and NCI-H460 (NSCLC) cells, respectively[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line:	HCT116, QG56, and NCI-H460 (NSCLC) cells
Concentration:	0-100 nM
Incubation Time:	72 hours
Result:	Was against human cancer cell lines, such as CRC and NSCLC cell lines.

REFERENCES

[1]. Anthoney DA, et al. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.BMC Cancer. 2012 Nov 21;12:536.

[2]. Niizuma S, et al. Synthesis of new camptothecin analogs with improved antitumor activities.Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA